Clinical Trials | Page 6 | Aplastic Anemia and MDS International Foundation

Clinical Trials

Clinical research is at the heart of all medical advances, identifying new ways to prevent, detect or treat disease. If you have a bone marrow failure disease, you may want to consider taking part in a clinical trial, also called a research study.

Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

Status(es): Recruiting
Study Date(s): Saturday, June 1, 2013 to Thursday, June 1, 2017
Disease(s): myelodysplastic syndromes (MDS)
Age Group:
This open label two-step phase II study is designed to determine the safety and efficacy of epigenetic priming with 5-Azacytidine immediately prior to reduced intensity conditioning for an in vivo T-cell depleted hematopoietic stem cell transplantation for high risk myeloid malignancies in complete remission (CR). Subjects will be given a five day course of subcutaneous 5-azacytidine, followed by a reduced intensity conditioning regimen of fludarabine and melphalan prior to an allogeneic hematopoietic stem cell transplantation from a related or unrelated HLA matched donor. The effect of 5-...

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

Status(es): Recruiting
Study Date(s): Tuesday, May 1, 2012 to Monday, May 1, 2017
Disease(s): myelodysplastic syndromes (MDS)
Age Group: up to 19 years old
Approximately 30% of patients who are candidates for bone marrow transplants do not have an HLA-matched, or close to matched, donor available. For this reason, doctors have been testing ways to make transplants from HLA-partially matched donors as safe and effective as transplants from HLA-matched donors. This study is being done to test the safety and the treatment results of a specific kind of transplant. In this transplant, blood from two donors will be used. Each donor will share one half of your HLA type. Blood from both donors will be transplanted at the same time.

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (BMT)

Status(es): Recruiting
Study Date(s): Monday, December 17, 2012 to Saturday, July 1, 2017
Disease(s):
Age Group: 18 years to 70 years
The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor. This is a pilot study, you are being asked to participate because you have a blood disorder and kidney disease. The aim of the combined transplant is to treat both your underlying blood disorder and kidney disease. We expect to have about 10 people participate in this study. Additionally, because the same person who is donating the kidney will also be donating the bone marrow, there may be a smaller chance of kidney...

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (BMT)

Status(es): Recruiting
Study Date(s): Thursday, November 1, 2012 to Saturday, July 1, 2017
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 18 to 70 years
The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor. This is a pilot study, you are being asked to participate because you have a blood disorder and kidney disease. The aim of the combined transplant is to treat both your underlying blood disorder and kidney disease. We expect to have about 10 people participate in this study. Additionally, because the same person who is donating the kidney will also be donating the bone marrow, there may be a smaller chance of kidney...

Busulfan and Cyclophosphamide Followed By ALLO BMT

Status(es): Recruiting
Study Date(s): Tuesday, January 1, 2013 to Monday, September 1, 2025
Disease(s): myelodysplastic syndromes (MDS)
Age Group: up to 44 year
This is a treatment guideline to allow routine clinical data to be collected and maintained in Oncore (clinical database) and the University of Minnesota Blood and Marrow Database as part of the historical database maintained by the department.

Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

Status(es): Recruiting
Study Date(s): Monday, June 6, 2016
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 1 to 65 years
The study is designed as a three arm randomized Phase III, multicenter trial comparing two calcineurin inhibitor (CNI)-free strategies for Graft-versus-Host Disease (GVHD) prophylaxis to standard tacrolimus and methotrexate (Tac/Mtx) in patients with hematologic malignancies undergoing myeloablative conditioning hematopoietic stem cell transplantation.

CC-486 (Oral Azacitidine) Bioequivalence Study in Patients With Solid Tumor or Hematologic Malignancies

Status(es): Recruiting
Study Date(s): Wednesday, October 1, 2014 to Thursday, June 2, 2016
Disease(s): myelodysplastic syndromes (MDS)
Age Group: 18 years and older
This is a Phase 1, open-label, multicenter, randomized, 2-period crossover study consisting of 2 phases: Pharmacokinetics and Extension. The study will enroll approximately 60 subjects with hematologic or solid tumor malignancies, excluding gastrointestinal tumors and tumors that have originated or metastasized to the liver. Approximately 8 sites in the US will participate in this study.

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Status(es): Recruiting
Study Date(s): Tuesday, February 11, 2014 to Friday, December 1, 2017
Disease(s): aplastic anemia, myelodysplastic syndromes (MDS)
Age Group: Up to 22 years
CD34+ stem cells (the cells that make all the types of blood cells in the body) are selected (removed) from the donor's peripheral blood stem cells. In doing this, T-cells (a type of blood cell) are also removed. T-cells are the cells which are responsible for severe acute and chronic graft versus host disease (GVHD). GVHD is a condition that results from a reaction of the transplanted donor T-lymphocytes (a kind of white blood cell) against the body and organs. There are two forms: acute (early) and chronic (late). Acute GVHD may produce skin rashes, liver disease, diarrhea, and an...

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Status(es): Recruiting
Study Date(s): Friday, November 1, 2013 to Friday, December 1, 2017
Disease(s): myelodysplastic syndromes (MDS)
Age Group: up to 22 years
This study is a research study involving subjects who are diagnosed with a malignant disease, that has either failed standard therapy or is unlikely to be cured with standard non-transplant therapy, who will receive a peripheral blood stem cell transplant. A malignant disease includes the following: Chronic Myeloid Leukemia (CML) in chronic phase, accelerated phase or blast crisis; Acute Myelogenous Leukemia (AML);Myelodysplastic Syndrome (MDS); Juvenile Myelomonocytic Leukemia (JMML); Acute Lymphoblastic Leukemia (ALL); or Lymphoma (Hodgkin's and Non-Hodgkin's) The purpose of this study is...

CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease

Status(es): Recruiting
Study Date(s): Thursday, October 17, 2013 to Sunday, December 1, 2019
Disease(s): aplastic anemia
Age Group: Up to 30 years
Graft-versus-host disease (GVHD) is a condition that results from a reaction of transplanted donor T-lymphocytes against the body and organs of the patient receiving the transplanted cells. There are two forms: acute (early) and chronic (late). Acute GVHD may produce skin rashes, liver disease,diarrhea, and an increased risk of infection. Chronic GVHD can appear in patients without prior acute GVHD. Chronic GVHD may also produce skin rashes, liver disease, diarrhea and an increased risk of infection. GVHD can make patients very sick, and having GVHD can make it more likely that patients will...